- Home
- PVL vs CGTX Comparison
PVL vs CGTX Comparison
Compare PVL & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PVL | CGTX |
|---|---|---|
| Founded | 2011 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.8M | 158.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | PVL | CGTX |
|---|---|---|
| Price | $1.83 | $1.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.88 |
| AVG Volume (30 Days) | 75.3K | ★ 942.9K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 20.11% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $3,511,891.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $28.88 | ★ N/A |
| Revenue Growth | ★ 11.77 | N/A |
| 52 Week Low | $1.30 | $0.22 |
| 52 Week High | $2.04 | $3.83 |
Technical Indicators
Market Signals| Indicator | PVL | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 44.64 | 53.10 |
| Support Level | $1.83 | $1.69 |
| Resistance Level | $1.90 | $1.77 |
| Average True Range (ATR) | 0.05 | 0.12 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 31.25 | 75.58 |
Price Performance
Historical ComparisonAbout PVL Permianville Royalty Trust Trust Units
Permianville Royalty Trust is a statutory trust which holds net profits interests in the profits from the sale of oil and natural gas production from non-operated assets of both conventional properties in the States of Texas, Louisiana, and New Mexico as well as unconventional assets in the Permian and Haynesville basins.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.